The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hormone Refractory Prostate Cancer-Global Market Insights and Sales Trends 2024
Synopsis
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
The global Hormone Refractory Prostate Cancer market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hormone Refractory Prostate Cancer in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers and Specialty Clinics,, are propelling Hormone Refractory Prostate Cancer market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hormonal Therapy segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Hormone Refractory Prostate Cancer market, driven by demand from China, the second largest economy with some signs of stabilising, the Hormone Refractory Prostate Cancer market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hormone Refractory Prostate Cancer, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hormone Refractory Prostate Cancer market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hormone Refractory Prostate Cancer market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hormone Refractory Prostate Cancer sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hormone Refractory Prostate Cancer covered in this report include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc.
The global Hormone Refractory Prostate Cancer market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Global Hormone Refractory Prostate Cancer market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hormone Refractory Prostate Cancer market, Segment by Type:
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Global Hormone Refractory Prostate Cancer market, by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hormone Refractory Prostate Cancer companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
The global Hormone Refractory Prostate Cancer market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hormone Refractory Prostate Cancer in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers and Specialty Clinics,, are propelling Hormone Refractory Prostate Cancer market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hormonal Therapy segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Hormone Refractory Prostate Cancer market, driven by demand from China, the second largest economy with some signs of stabilising, the Hormone Refractory Prostate Cancer market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hormone Refractory Prostate Cancer, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hormone Refractory Prostate Cancer market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hormone Refractory Prostate Cancer market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hormone Refractory Prostate Cancer sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hormone Refractory Prostate Cancer covered in this report include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc.
The global Hormone Refractory Prostate Cancer market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Global Hormone Refractory Prostate Cancer market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hormone Refractory Prostate Cancer market, Segment by Type:
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Global Hormone Refractory Prostate Cancer market, by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hormone Refractory Prostate Cancer companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Hormone Refractory Prostate Cancer
1.1 Hormone Refractory Prostate Cancer Market Overview
1.1.1 Hormone Refractory Prostate Cancer Product Scope
1.1.2 Hormone Refractory Prostate Cancer Market Status and Outlook
1.2 Global Hormone Refractory Prostate Cancer Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hormone Refractory Prostate Cancer Market Size by Region (2018-2029)
1.4 Global Hormone Refractory Prostate Cancer Historic Market Size by Region (2018-2023)
1.5 Global Hormone Refractory Prostate Cancer Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hormone Refractory Prostate Cancer Market Size (2018-2029)
1.6.1 North America Hormone Refractory Prostate Cancer Market Size (2018-2029)
1.6.2 Europe Hormone Refractory Prostate Cancer Market Size (2018-2029)
1.6.3 Asia-Pacific Hormone Refractory Prostate Cancer Market Size (2018-2029)
1.6.4 Latin America Hormone Refractory Prostate Cancer Market Size (2018-2029)
1.6.5 Middle East & Africa Hormone Refractory Prostate Cancer Market Size (2018-2029)
2 Hormone Refractory Prostate Cancer Market by Type
2.1 Introduction
2.1.1 Chemotherapy
2.1.2 Hormonal Therapy
2.1.3 Immunotherapy
2.1.4 Radiation Therapy
2.2 Global Hormone Refractory Prostate Cancer Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hormone Refractory Prostate Cancer Historic Market Size by Type (2018-2023)
2.2.2 Global Hormone Refractory Prostate Cancer Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hormone Refractory Prostate Cancer Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hormone Refractory Prostate Cancer Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hormone Refractory Prostate Cancer Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hormone Refractory Prostate Cancer Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hormone Refractory Prostate Cancer Revenue Breakdown by Type (2018-2029)
3 Hormone Refractory Prostate Cancer Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Ambulatory Surgical Centers
3.1.3 Specialty Clinics
3.2 Global Hormone Refractory Prostate Cancer Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hormone Refractory Prostate Cancer Historic Market Size by Application (2018-2023)
3.2.2 Global Hormone Refractory Prostate Cancer Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hormone Refractory Prostate Cancer Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hormone Refractory Prostate Cancer Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hormone Refractory Prostate Cancer Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hormone Refractory Prostate Cancer Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hormone Refractory Prostate Cancer Revenue Breakdown by Application (2018-2029)
4 Hormone Refractory Prostate Cancer Competition Analysis by Players
4.1 Global Hormone Refractory Prostate Cancer Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hormone Refractory Prostate Cancer as of 2022)
4.3 Date of Key Players Enter into Hormone Refractory Prostate Cancer Market
4.4 Global Top Players Hormone Refractory Prostate Cancer Headquarters and Area Served
4.5 Key Players Hormone Refractory Prostate Cancer Product Solution and Service
4.6 Competitive Status
4.6.1 Hormone Refractory Prostate Cancer Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Astellas Inc
5.1.1 Astellas Inc Profile
5.1.2 Astellas Inc Main Business
5.1.3 Astellas Inc Hormone Refractory Prostate Cancer Products, Services and Solutions
5.1.4 Astellas Inc Hormone Refractory Prostate Cancer Revenue (US$ Million) & (2018-2023)
5.1.5 Astellas Inc Recent Developments
5.2 Sanofi S.A
5.2.1 Sanofi S.A Profile
5.2.2 Sanofi S.A Main Business
5.2.3 Sanofi S.A Hormone Refractory Prostate Cancer Products, Services and Solutions
5.2.4 Sanofi S.A Hormone Refractory Prostate Cancer Revenue (US$ Million) & (2018-2023)
5.2.5 Sanofi S.A Recent Developments
5.3 Dendreon Corporation, Bayer AG
5.3.1 Dendreon Corporation, Bayer AG Profile
5.3.2 Dendreon Corporation, Bayer AG Main Business
5.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Products, Services and Solutions
5.3.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Revenue (US$ Million) & (2018-2023)
5.3.5 Johnson & Johnson Recent Developments
5.4 Johnson & Johnson
5.4.1 Johnson & Johnson Profile
5.4.2 Johnson & Johnson Main Business
5.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer Products, Services and Solutions
5.4.4 Johnson & Johnson Hormone Refractory Prostate Cancer Revenue (US$ Million) & (2018-2023)
5.4.5 Johnson & Johnson Recent Developments
6 North America
6.1 North America Hormone Refractory Prostate Cancer Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Hormone Refractory Prostate Cancer Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hormone Refractory Prostate Cancer Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hormone Refractory Prostate Cancer Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hormone Refractory Prostate Cancer Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hormone Refractory Prostate Cancer Market Dynamics
11.1 Hormone Refractory Prostate Cancer Industry Trends
11.2 Hormone Refractory Prostate Cancer Market Drivers
11.3 Hormone Refractory Prostate Cancer Market Challenges
11.4 Hormone Refractory Prostate Cancer Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
